arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Compass Therapeutics, Inc.

CMPX
$2.15 ▲ +0.16 (+7.79%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
34 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Compass Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $400.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.6%
FCF / Share $-0.09
Trailing P/E
Price / Book 2.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-18.32M
↓ -10.1%
FCF / Share Free cash flow per share
$-0.09
↑ +2.7%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters